株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

呼吸器合胞体(RS)ウィルス付着糖タンパク質(G/RSV-G):パイプライン製品の分析

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 365796
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.65円で換算しております。
呼吸器合胞体(RS)ウィルス付着糖タンパク質(G/RSV-G):パイプライン製品の分析 Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 38 Pages
概要

当レポートでは、呼吸器合胞体(RS)ウィルス付着糖タンパク質(G/RSV-G)を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

呼吸器合胞体(RS)ウィルス付着糖タンパク質(G/RSV-G) 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Agilvax, Inc.
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Trellis Bioscience, Inc.

薬剤プロファイル

休止中のプロジェクト

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Bavarian Nordic A/S, H2 2019
  • Pipeline by Visterra Inc, H2 2019
  • Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC1947TDB

Summary:

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 7 molecules. The latest report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.

Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
  • The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
    • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Bavarian Nordic A/S
    • Visterra Inc
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
    • Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MVA-RSV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRL-3D3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIS-RSV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
  • Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix